Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease☆,☆☆,★,★★
Section snippets
Study Population
Charts of patients with SCD seen at least once since 1989 in the Children’s Hospital (Boston, Mass.) Hematology Clinic were reviewed. Patients <2 years of age or those who had received pneumococcal vaccine within the previous 2 years were excluded. Eligible patients were contacted by mail. The study was approved by the Children’s Hospital Committee on Clinical Investigation. Informed consent was obtained from each participant or parent/guardian.
Study Design
Subjects were randomized to receive a single dose
Subject Characteristics (Table I)
One hundred eighty-one eligible patients were identified. Six had moved out of state, 59 could not be contacted by mail or phone, and 93 declined participation. The remaining 23 patients were enrolled, and all subjects completed the study.
Empty Cell 23V Vaccine only group (n = 12) 7V + 23V Vaccine group (n = 11) Diagnosis Empty Cell Empty Cell Hgb SS 7 6 Hgb SC 2 4 Hgb S-β Thal0 2 1 Hgb S-β Thal+ 1 0 Median age in years (range) 14 (4-30) 13 (4-27) Male:female 7:5 3:8 Previous splenectomy 0 2 Previous
Discussion
In our study subjects who received two doses of pneumococcal-conjugate vaccine followed by 23-valent vaccine achieved higher GMC for all serotypes contained in the conjugate vaccine compared with those who received 23-valent vaccine only. For subjects who received conjugate vaccine (which contains only 2 to 4 μg of each capsular polysaccharide compared with 25 μg of each polysaccharide in the 23-valent vaccine), GMC increased significantly after the first dose for all serotypes except 6B. This
Acknowledgements
The authors thank Donna Ambrosino, MD, for review of the article, the nursing and administrative staff of Children’s Hospital General Clinical Research Center for their assistance, and the respective vaccine manufacturers for donating vaccine for the study.
References (12)
- et al.
Clinical events in the first decade in a cohort of infants with sickle cell disease
Blood
(1995) - et al.
Bacteremia in sickle hemoglobinopathies
J Pediatr
(1986) - et al.
Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease
J Pediatr
(1996) - et al.
Pneumococcal colonization in children with sickle cell disease
J Pediatr
(1996) - et al.
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
J Pediatr
(1996) - et al.
Pneumococcal vaccine in normal children
Am J Dis Child
(1983)
Cited by (104)
Sickle Cell Disease: A Brief Update
2017, Medical Clinics of North AmericaCitation Excerpt :As a result, maintaining updated immunizations and routine prophylactic penicillin for all children younger than 5 years is paramount to prevent poor outcomes associated with these infections. All people with SCD should be vaccinated against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B, as well as for hepatitis B virus and seasonal influenza in addition to all other standard vaccines.43–45 It is equally important to educate patients of all ages and their families to seek medical care should they develop signs of infection, for example, for any temperature higher than 101.3°F or 38.5°C due to the risk for bacterial infections.32
Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
2017, Plotkin's VaccinesVaccination of Immunocompromised Hosts
2017, Plotkin's VaccinesVaccinations in patients with hematological malignancies
2016, Blood ReviewsPneumococcal conjugate vaccine and pneumococcal common protein vaccines
2012, Vaccines: Sixth Edition
- ☆
From the Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, Massachusetts; the Department of Epidemiology and Biostatistics, Boston University School of Public Health, Boston, Massachusetts; and the Division of Hematology/Oncology, Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
- ☆☆
Supported in part by a General Clinical Research grant to Children’s Hospital from the National Institutes of Health (M01RR02172). Dr. Vernacchio was supported by a Boston University School of Public Health training grant in Perinatal, Infant, and Child Epidemiology from the National Institutes of Health (5T32HD0748802). Dr. Neufeld was a fellow of the Lucille P. Markey trust.
- ★
Reprint requests: Deborah C. Molrine, MD, MPH, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115.
- ★★
0022-3476/98/$5.00 + 0 9/22/90348